Weinstein E, Paredes R, Gardner A, Almas M, et al. Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. Lancet Infect Dis 2025 Jul 14:S1473-3099(25)00221.
PMID: 40675169